Start-up India Seed Fund Scheme (SISFS)

You are here

Start-up India Seed Fund Scheme (SISFS)

C-CAMP has partnered with DPIIT for the disbursement of Start-up India Seed Fund Scheme (SISFS) to provide financial assistance to start-ups for Proof of Concept, prototype development, product trials, market entry, and commercialization. The scheme is positioned to provide a financial cushion among Indian start-ups that suffer from capital inadequacy in the seed and ‘Proof of Concept’ development stage.


  • Up to Rs. 20 Lakhs as grant for validation of Proof of Concept, or prototype development, or product trials disbursed in milestone-based instalments.
  • Up to Rs. 50 Lakhs of investment for market entry, commercialization, or scaling up through convertible debentures or debt or debt-linked instruments
  • A start-up applicant can avail seed support in the form of grant and / or debt/convertible debentures each once as per the guidelines of the scheme


  • Start-up should be recognised by DPIIT and not be more than 2 years old. Individual entrepreneurs are ineligible for this scheme.
  • Start-up should not have received more than Rs 10 lakh of monetary support under any other Central or State Government scheme.
  • Shareholding pattern should be at least 51% by Indian promoters
  • Start-up should have a business model and have a sound commercialization strategy and road map to the market
  • Innovative solutions in sectors such as social impact, waste management, water management, financial inclusion, education, agriculture, food processing, biotechnology, healthcare, energy, mobility, defence, space, railways, oil and gas, textiles are preferred
  • A start-up applicant can avail seed support in the form of grant and debt/convertible debentures each once as per the guidelines of the scheme.

Selection Criteria:

  • There is no minimum education qualification required for founders to apply for SISFS.
  • Detailed eligibility criteria can be found at
  • Private Limited Company or Registered Partnership Firm or Limited Liability Partnership can apply. A sole proprietorship or a public limited company is not eligible as start-up.
  • If its turnover of the start-up for any of the financial years has not exceeded INR 100 crore
  • Start-up should not have been formed by splitting up or reconstruction of a business already in existence.

Apply at:

For DPIIT recognition:

Contact us:

For further info please contact:; +91-80-67185055

Centre for Cellular and Molecular Platforms, NCBS-TIFR, GKVK, Bellary Road, Bangalore 560065, India


Start-ups funded under Start-up India Seed Fund Scheme (SISFS)

Brainiac Healthcare Pvt Ltd (Medtech)

The vision for Brainiac Healthcare is to develop phygital medical devices for healthcare professionals to reduce the cost of the medical equipment and make it upgraded with time with latest technologies like AI, AR/VR, IOT, etc. Currently, the team are building a respiratory CO2 monitoring device called RespiCOz for Anaesthesiologist to monitor the concentration of CO2 gas in their patients breathing in real-time on their mobile phone. It is a portable, easy-to-use and mobile app operated device which helps them to carry it anywhere to treat their patience. RespiCOz can help Anaesthesiologists to monitor their patients’ metabolic activities which can help them to make quick decisions on their patients.


Prodancy Pvt Ltd

Prodancy develops respiratory protection devices for healthcare professionals. Its two co-founders Venkatesh Parthasarathy and Pradeep Vamana have 23 years of experience in industrial design as well as Sales & Strategy, respectively. Prodancy developed & launched its first product Vizbl, the world’s lightest surgical helmet for Orthopedic joint replacement surgeons in Feb 2023. Vizbl protects surgeons and patients from potential infections. Vizbl surgical helmet is 40% lighter, 50% more affordable and has no-chin bar design ensuring greater surgeon comfort. Since April 2023, over 110 Vizbl surgical helmets are sold and over 4000 surgeries are performed using Vizbl by Orthopedic joint replacement surgeons across India. Prodancy also has a pan-India distribution network.



immunitoAI is an antibody therapeutics company based out of Bangalore (India) that is developing an AI-platform for discovering and developing novel biologics with pre-defined drug properties entirely using AI. The AI-platform is built to be capable of generating de novo antibody and antibody fragments (single-domain antibody - SdAb, single-chain Fragment variable - scFv, full-length antibodies and multispecific antibodies) against any epitope and does not depend upon a biological source, animal or human, for the lead molecule. The predictions from the AI are further validated in their in-house biological lab. immunitoAI has successfully developed the end-to-end AI pipeline required for antibody discovery and generated a first set of single domain antibodies (SdAb) that were biologically validated through experimentation.


NKure Therapeutics

The technology driving NKure is engineering NK cells with chimeric antigen receptors (CARs) targeted against molecular markers of cancer. The CAR-NK will be expanded and activated by an in-house feeder platform that will allow the cells to grow to clinically relevant numbers. The expanded and activated CAR-NKs are infused into the body; target specificity by the CARs will allow the engineered NK cells to seek out cancer cell markers. They will then eliminate the cancer using the mechanism of cytotoxic CAR-NK cells.


Ultranutri Pvt Ltd

UltraNutri is an agri-biotech startup based out of CCAMP, a DBT promoted bio-incubator and works in collaboration with ICAR-CIBA. The company is currently working towards developing a "blueprint" for India's biggest "Insect Factory" and subsequently launching the "NexGen Functional" shrimp feed over the course 12-18 months. UltraNutri has developed a 3 step biotech process to utilise agri-residues such as sugarcane bagasse and coffee husk as feedstock/substrate for rearing Black Soldier Fly Larvae. This process brings the cost of BSF to price parity with fishmeal and also promotes expression of defence peptides. In collaboration with ICAR-CIBA, we have developed BSF based Shrimp feed having better growth and survivability. These lab results are currently being validated through field trials. The product is expected to increase shrimp farmer income through better growth and reduce economic loss due to disease occurrence.



Inovaugmet has been focusing on safe and effective small molecules for hair regeneration to treat Androgen Alopecia also known as pattern hair loss which affects more than 50 percent of population. The technological strategy is centred on finding and validating new drug targets leveraging in-house cutting-edge iNeu-3D screen platform. This innovative platform harnesses the power of latest advancements in cell biology, genetics, computational biology, and molecular biology to provide a deeper understanding of human skin biology, disease mechanisms.


Tellus Habitat

With a motto of "Pioneering Worldwide Water Resilience by redefining STPs", Tellus Habitat provides sustainable technologies for the treatment and reclamation of wastewater by an elective mix of scientists and researchers from the Indian Institute of Science, Bengaluru. Our innovative and proven technologies have been developed with research and field testing over the decades which provides water security to individual households, communities, and apartments. The team’s newest launch R3H2O-"Water Recycle.Reuse.Reinvented" is an advanced automatic water recycler. This has been crafted and developed to address unique requirements of municipal wastewater treatment by employing proprietary pulse mode technology. This unlocks energy savings of >50% while adhering to regulatory standards. In the inaugural phase of implementation strategy, The team have designed decentralized wastewater treatment units catering to capacities ranging from 5000 to 50000 L/d.


BioLOCKEY Healthworks Pvt Ltd (Medtech)

Breaking away from conventional PCR methods confined to centralized laboratories, bioLOCKEY Healthworks is developing portable, rapid, and remarkably sensitive diagnostic solutions, utilizing engineered single-domain Nanobodies. This innovative approach thrives on the recently developed all-in-one NANOdx platform. The team has leveraged the knowledge of antigen-Nanobody molecular interactions to develop highly functional repertoires to surpass the diversity and functionality of the natural immune system. This engineered system will enable instrument-free molecular screening and diagnosis, boast a rapid turnaround time, offering a "sample-in-answer-out" workflow. This simplicity aligns perfectly with the envisioned "screen and treat" strategy, making it an ideal fit for low-resource settings where time and resources are precious commodities.